As a result of the therapeutic advances and clinical research affecting the management of patients with cancer, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers. This peer interaction is an integral part in enhancing clinical decision-making skills that can improve patient care.

Clinicians need to be informed about the importance of MSI-H/dMMR testing in patients with GI tumors and updated on the most recent clinical evidence to ensure that they select the most appropriate treatment options for their patients.

It is critical for individuals with a family history of Lynch syndrome to have genetic counseling and testing in order to identify those who are at risk and implement appropriate screening, surveillance, and risk-reduction strategies based on the individual’s risk profile. Clinicians need to recognize the role of genetic testing and counseling and the importance of a personalized and patient-centric approach to care of individuals with a hereditary cancer syndrome.

Continued education on the advancements of colorectal cancer will help bridge knowledge gaps and improve the quality of care offered to patients.

As the clinical understanding of biomarkers in colorectal cancer has deepened, it has become increasingly clear that deficient mismatch repair or microsatellite instability-high (dMMR/MSI-H) colorectal cancer should be treated differently from proficient mismatch repair or microsatellite stable (pMMR/MSS) disease in order to reach the best possible outcomes for patients.

As the clinical understanding of biomarkers in colorectal cancer has deepened, it has become increasingly clear that deficient mismatch repair or microsatellite instability-high (dMMR/MSI-H) colorectal cancer should be treated differently from proficient mismatch repair or microsatellite stable (pMMR/MSS) disease in order to reach the best possible outcomes for patients.

Targeted therapy approaches for mCRC continue to evolve as new data helps define how to best improve outcomes. Decisions regarding treatment for patients with mCRC require that clinicians be familiar with existing and new targeted therapies as well as the most effective and tolerable combination regimens.

It is difficult for clinicians to stay current with the evolving treatment options for colorectal cancer, and they can benefit from education about these therapies.

It is difficult for clinicians to stay current with the evolving treatment options for colorectal cancer, and they can benefit from education about these therapies.